Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
minocycline + methotrexate
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Minocycline + methotrexate is a combination of two small molecule drugs used primarily in the treatment of rheumatoid arthritis. Minocycline is a tetracycline-class antibiotic with anti-inflammatory properties, while methotrexate is an antimetabolite and antifolate agent that acts as a disease-modifying antirheumatic drug (DMARD). The combination has been studied for its potential to improve symptoms and slow disease progression in early rheumatoid arthritis. Minocycline exerts its effects by inhibiting bacterial protein synthesis and modulating inflammatory pathways, whereas methotrexate inhibits dihydrofolate reductase, interfering with DNA synthesis and immune cell proliferation. Clinical studies suggest the combination may be well tolerated but does not significantly increase efficacy or toxicity compared to monotherapy[3][4][6].
- Other names
- minocycline and methotrexateminocycline plus methotrexateMTX + minocycline
02
Targets
DHFR (Dihydrofolate reductase)Bacterial Ribosome
Beyond the preview
Go deeper on minocycline + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on minocycline + methotrexate.